Month: February 2021

In the 2020 financial year (1 January – 31 December), Tallink Grupp AS and its subsidiaries (the Group) carried a total of 3 732 102 passengers, which is 62% passengers less compared to the 2019 financial year. The number of cargo units transported decreased by 5.2% compared to the previous financial year. The Group’s unaudited consolidated revenue amounted to EUR 442.9 million (EUR 949.1 million in 2019). Unaudited EBITDA was EUR 8.0 million (EUR 171.1 million, 2019) and unaudited net loss for the financial year was EUR 108.3 million or EUR 0.16 per share (net profit of EUR 49.7 million or EUR 0.07 per share, 2019).Impact of Covid-19 and travel restrictionsIn the 2020 financial year, the Group’s operations and operating results were strongly influenced by the Covid-19 situation, restrictions on international travel and communications...

In the 2020 financial year (1 January – 31 December), Tallink Grupp AS and its subsidiaries (the Group) carried a total of 3 732 102 passengers, which is 62% passengers less compared to the 2019 financial year. The number of cargo units transported decreased by 5.2% compared to the previous financial year. The Group’s unaudited consolidated revenue amounted to EUR 442.9 million (EUR 949.1 million in 2019). Unaudited EBITDA was EUR 8.0 million (EUR 171.1 million, 2019) and unaudited net loss for the financial year was EUR 108.3 million or EUR 0.16 per share (net profit of EUR 49.7 million or EUR 0.07 per share, 2019).Impact of Covid-19 and travel restrictionsIn the 2020 financial year, the Group’s operations and operating results were strongly influenced by the Covid-19 situation, restrictions on international travel and communications...

Tallink Grupp AS ja tema tütarettevõtted (edaspidi „Kontsern“) vedasid 2020. majandusaastal (1. jaanuar – 31. detsember) kokku 3 732 102 reisijat, mida on 62% võrra vähem kui 2019. aastal. Veetud kaubaveoühikute arv langes 5,2% võrra võrreldes eelmise majandusaastaga. Kontserni auditeerimata konsolideeritud müügitulu oli 442,9 miljonit (2019: 949,1 miljonit eurot). Auditeerimata kulumieelne ärikasum (EBITDA) oli 8,0 miljonit eurot (2019: 171.1 miljonit eurot) ja auditeerimata puhaskahjum oli 108,3 miljonit eurot või 0,16 eurot aktsia kohta (2019: 49,7 miljonit eurot või 0,07 eurot aktsia kohta).Koroonaviiruse haiguse mõju (Covid-19) ja reisipiirangud2020. majandusaasta tegevustele ja tulemustele avaldasid ulatuslikku mõju Covid-19 kaasnenud olukord, rahvusvahelised reisipiirangud ning reisimist mittesoosiv kommunikatsioon ametivõimudelt....

Wilson ASA: Endelig årsregnskap 2020Vedlagt følger endelig regnskap for 2020 for Wilson ASA konsern og morselskap.Vedlegget inneholder styrets beretning for 2020 inklusive prinsipper for eierstyring og selskapsledelse, årsregnskap med noter for morselskap og konsern samt revisors beretning.I egne vedlegg følger selskapets ESG rapport og likestillingsredegjørelse som er en del av styrets beretning.Wilson ASABergen, 25. februar 2021Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12VedleggWilson ASA_konsernregnskap 2020Wilson ASA ESG rapport 2020Wilson ASA Likestillingsredegjorelse 2020

Wilson Asa rapporterer sterk avslutning på 2020.Markedet tok seg kraftig opp mot slutten av året som resulterte i selskapets beste kvartal i historien målt på EBITDA.Økte råvarepriser, støtte og stimulansepakker og lavt rentenivå bidrar til økt aktivitetsnivå i selskapets forretningsområde på tross av Covid-19 usikkerheten. Kombinert med en allerede stram tilbudsside, der Covid-19 har redusert alternative transportalternativer samt medført noe økt tidsbruk, gir det samlet sett utslag i god etterspørsel etter selskapets tjenester.For fjerde kvartal 2020 oppnådde konsernet brutto fraktinntekter på MEUR 75,3, som er MEUR 5,2 høyere enn i fjerde kvartal 2019. Konsernets driftskostnader er på tilsvarende nivå som i fjor, MEUR 24,3 i fjerde kvartal 2020 mot MEUR 24,2 i fjerde kvartal 2019. Konsernet leverer et driftsresultat før avskrivninger...

The Group has released its full-year 2020 earnings presentation on its website. It is available following this link:https://www.groupe-casino.fr/wp-content/uploads/2021/02/Presentation-RIF-2020-VA.pdfANALYST AND INVESTOR CONTACTSLionel Benchimol – +33 (0)1 53 65 64 17lbenchimol@groupe-casino.fror+33 (0)1 53 65 24 17IR_Casino@groupe-casino.frPRESS CONTACTSCasino Group – Communications DepartmentStéphanie Abadie – sabadie@groupe-casino.fr – +33 (0)6 26 27 37 05or+33 (0)1 53 65 24 78 – directiondelacommunication@groupe-casino.frAgence IMAGE 7Karine Allouis – +33 (0)1 53 70 74 84 – kallouis@image7.frFranck Pasquier – +33 (0)6 73 62 57 99 – fpasquier@image7.fr Disclaimer This press release was prepared solely for information purposes, and should not be construed as a solicitation or an offer to buy or sell securities or related financial...

Le Groupe indique qu’il a mis à disposition du public sa présentation des résultats 2020 sur son site à l’adresse suivante :https://www.groupe-casino.fr/wp-content/uploads/2021/02/Presentation-RIF-2020-VF.pdf CONTACTS ANALYSTES ET INVESTISSEURSLionel BENCHIMOL – Tél : +33 (0)1 53 65 64 17lbenchimol@groupe-casino.frou+33 (0)1 53 65 24 17IR_Casino@groupe-casino.frCONTACTS PRESSEGroupe Casino – Direction de la CommunicationStéphanie ABADIE – sabadie@groupe-casino.fr – +33 (0)6 26 27 37 05ou+33(0)1 53 65 24 78 – directiondelacommunication@groupe-casino.frAgence IMAGE 7Karine ALLOUIS – Tel : +33(0)1 53 70 74 84 – kallouis@image7.frFranck PASQUIER – Tel : +33 (0)6 73 62 57 99 – fpasquier@image7.fr Disclaimer Ce communiqué a été préparé uniquement à titre informatif et ne doit pas être interprété comme une sollicitation...

SECOND-HALF 2020 RESULTSVery strong growth in banners and e-commerce profitability,enabling the Group to pursue its deleveragingAfter a first-half performance affected by costs related to the health crisis, profitability improved strongly in the second half in both France and Latin AmericaSharp reduction in gross and net debtOutlook for 2021: profitable growth, cash flow generation and continued debt reductionGroup EBITDA in H2: +11%                         Group EBITDA (after lease payments) in H2: +20%      Group Trading profit in H2: +20%+6% in France, 11.5% margin (+164bps)       · +13% in France, 7.8% margin  (+152bps)                   ·+4% in France, 6.1% margin (+79bps)+18% in Latam, 9.7% margin (+260bps)       · +30% in Latam, 7.9% margin (+265bps)                   ·+42% in Latam, 6.9% margin (+275bps)             Group gross...

En FrRESULTATS SECOND SEMESTRE 2020Très forte croissance de la rentabilité des enseignes et due-commerce, permettant la poursuite du désendettement du GroupeAprès un premier semestre marqué par l’impact des coûts liés à la crise sanitaire, le second semestre a montré une forte amélioration de la rentabilité tant en France qu’en Amérique latineForte réduction de la dette brute et de la dette nettePerspectives 2021 : croissance rentable, génération de cash-flow et poursuite du désendettementEBITDA Groupe S2: +11%                          EBITDA après loyers Groupe S2: +20%     ROC Groupe S2: +20%+6% en France, marge 11,5% (+164bps)  · +13% en France, marge: 7,8% (+152bps)  · +4% en France, marge: 6,1% (+79bps)+18% au Latam, marge 9,7% (+260bps)  · +30% au Latam, marge: 7,9% (+265bps)  · +42% au Latam, marge: 6,9% (+275bps)Dette brute Groupe...

Positive Phase 2 results with pMDI ensifentrine in COPDEnrollment ongoing in ENHANCE Phase 3 program Up to $30 million debt finance facility increases financial flexibilityConference call today at 9:00 a.m. EST / 2:00 p.m. GMTLONDON and RALEIGH, N.C., Feb. 25, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2020, and provides a corporate update.“2020 was a transformative year for Verona Pharma,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “We started the year with positive data from a Phase 2b trial where nebulized ensifentrine demonstrated clinically meaningful improvements in lung function...